“We seek to confirm that clinical trials can move ahead using this new supply of organs with the tried-and-true transplant practices we have perfected at the NYU Langone Transplant Institute,” Moazami said.Īlex Reyentovich, director of the NYU Langone Advanced Heart Failure program, said these latest advances in xenotransplantation move the field closer to realising a new supply of organs for those facing life-threatening diseases. “Our goal is to integrate the practices used in a typical, everyday heart transplant, only with a nonhuman organ that will function normally without additional aid from untested devices or medicines,” Moazami said in a statement. “Both had been declared formally brain dead-on ventilatory support and dialysis-and were not deemed eligible for traditional organ donation but seemed stable enough to undergo the transplant surgery for the purpose of gaining experimental insights,” according to a report. The recipients of the NYU procedure were 72-year-old Lawrence Kelly and a 64-year-old woman whose name was withheld. David Bennett (57) was the first living person to receive a genetically modified pig’s heart. The NYU surgeons used the same genetically modified pig hearts manufactured by Revivicor that was transplanted in a man with terminal heart disease by surgeons at the University of Maryland Medical Center (UMMC) in January this year. The procurement, transport, transplant surgery, and immunosuppression were aligned with current clinical standards used in heart transplantation. No other investigational devices or medications were used in the study. The hearts were procured from pigs that had 10 genetic modifications, including 4 porcine gene “knockouts” to prevent rejection and abnormal organ growth as well as six human transgenes to promote expression of proteins that regulate important biologic pathways that can be disrupted by incompatibilities between pigs and humans. The operating room used for the study has been taken offline to be used only for future xenotransplantation research, they said. No presence of porcine cytomegalovirus (pCMV), which can cause an infection, was detected in either case. No signs of early rejection were observed in either organ and the hearts functioned normally with standard post-transplant medications and without additional mechanical support, the researchers said. The first heart xenotransplant concluded on June 19, 2022, and the second on July 9, 2022. The transplant surgeries were performed over several hours and heart function was monitored for three days. Nader Moazami, surgical director of heart transplantation at the NYU Langone Transplant Institute, led the investigational procedures using hearts procured from a facility hundreds of miles away and transplanted into recently deceased donors maintained on ventilator support, according to a press release. The surgeries, known as xenotransplants (inter-species organ transplant) were performed on June 16 and July 6, the surgeons said. New Delhi: Surgeons at New York University (NYU) Langone’s Tisch Hospital have announced that they have successfully transplanted genetically-engineered pig hearts into brain-dead humans, saying the development marks an advance towards the long-term goal of performing such surgeries regularly in living patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |